P-glycoprotein inhibition: The past, the present and the future

Current Drug Metabolism

Volumn 12, Issue 8, 2011, Pages 722-731

  Darby, Richard A J ^a   Callaghan, Richard ^a   McMahon, Róisín M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

ABC transporter; Chemotherapy; Cytochrome P450; Drug metabolism; Multidrug resistance; P gp

Indexed keywords

CREMOPHOR; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; ELACRIDAR; FRUCTUS SCHIZANDRAE EXTRACT; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; PACLITAXEL; PLANT EXTRACT; SILIBININ; TARIQUIDAR; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINCRISTINE; ZOSUQUIDAR;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; COMPUTER MODEL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMAN; HYPERBILIRUBINEMIA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; REVIEW;

EID: 80053471265     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011798357006     Document Type: Review

References (106)

1. Juliano, R. L.; Ling, V., Surface Glycoprotein Modulating DrugPermeability In Chinese-Hamster Ovary Cell Mutants. BiochimicaEt. Biophysica Acta, 1976, 455 (1), 152-162.
2. Cole, S. P. C.; Bhardwaj, G.; Gerlach, J. H.; Mackie, J. E.; Grant,C. E.; Almquist, K. C.; Stewart, A. J.; Kurz, E. U.; Duncan, A. M.V.; Deeley, R. G., Overexpression Of A Transporter Gene In AMultidrug-Resistant Human Lung-Cancer Cell-Line. Science, 1992,258 (5088), 1650-1654. (Pubitemid 23012438)
3. Doyle, L. A.; Yang, W. D.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.M.; Rishi, A. K.; Ross, D. D., A multidrug resistance transporterfrom human MCF-7 breast cancer cells. P. Natl. Acad. Sci. USA.1998, 95 (26), 15665-15670. (Pubitemid 29018757)
4. Wrighton, S. A.; VandenBranden, M.; Ring, B. J., The human drugmetabolizing cytochromes P450. J. Pharmacokinet. Biopharm.,1996, 24 (5), 461-473.
5. Nebert, D. W.; Russell, D. W., Clinical importance of thecytochromes P450. Lancet, 2002, 360 (9340), 1155-1162.
6. Thorn, M.; Finnstrom, N.; Lundgren, S.; Rane, A.; Loof, L.,Cytochromes P450 and MDR1 mRNA expression along the humangastrointestinal tract. Br. J. Clin. Pharmacol., 2005, 60 (1), 54-60. (Pubitemid 40942781)
7. von Richter, O.; Burk, O.; Fromm, M. F.; Thon, K. P.; Eichelbaum,M.; Kivisto, K. T., Cytochrome P450 3A4 and P-glycoproteinexpression in human small intestinal enterocytes and hepatocytes:A comparative analysis in paired tissue specimens. Clin.Pharmacol. Ther., 2004, 75 (3), 172-183. (Pubitemid 38314866)
8. Sadeque, A. J. M.; Wandel, C.; He, H.; Shah, S.; Wood, A. J. J.,Increased drug delivery to the brain by P-glycoproteininhibition[ast]. Clin. Pharmacol. Ther., 2000, 68 (3), 231-237.
9. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y., Overcoming OfVincristine Resistance In P388 Leukemia Invivo And InvitroThrough Enhanced Cyto-Toxicity Of Vincristine And VinblastineBy Verapamil. Cancer Res., 1981, 41 (5), 1967-1972. (Pubitemid 11114605)
10. Yusa, K.; Tsuruo, T., Reversal Mechanism Of MultidrugResistance By Verapamil - Direct Binding Of Verapamil To PGlycoproteinOn Specific Sites And Transport Of VerapamilOutward Across The Plasma-Membrane Of K562 Adm Cells.Cancer Res., 1989, 49 (18), 5002-5006. (Pubitemid 19239333)
11. Ozols, R. F.; Cunnion, R. E.; Klecker, R. W.; Hamilton, T. C.;Ostchega, Y.; Parrillo, J. E.; Young, R. C., Verapamil AndAdriamycin In The Treatment Of Drug-Resistant Ovarian-CancerPatients. J. Clin. Oncol., 1987, 5 (4), 641-647. (Pubitemid 17062504)
12. Anglicheau, D.; Pallet, N.; Rabant, M.; Marquet, P.; Cassinat, B.;Meria, P.; Beaune, P.; Legendre, C.; Thervet, E., Role of Pglycoproteinin cyclosporine cytotoxicity in the cyclosporinesirolimusinteraction. Kidney Int., 2006, 70 (6), 1019-1025. (Pubitemid 44344071)
13. Friche, E.; Buhl Jensen, P.; Nissen, N. I., Comparison ofcyclosporin A and SDZ PSC833 as multidrug-resistancemodulators in a daunorubicin-resistant Ehrlich ascites tumor.Cancer Chemotherapy and Pharmacology, 1992, 30 (3), 235-237.
14. Boesch, D.; Gavériaux, C.; Jachez, B.; Pourtier-Manzanedo, A.;Bollinger, P.; Loor, F., In Vivo Circumvention of P- GlycoproteinmediatedMultidrug Resistance of Tumor Cells with SDZ PSC 833.Cancer Res., 1991, 51 (16), 4226-4233.
15. Dalton, W.; Greipp, P.; Greenberg, P.; Stiff, P.; Ballester, O.;Friedenberg, W.; Salmon, S.; Kyle, R.; Charnick, S.; Pearce, T.,Phase I study of the chemosensitizer SDZ PSC 833 in combinationwith VAD chemotherapy to reverse multidrug resistance. Blood1996, 88 (10), 2638-2638.
16. Fellner, S.; Bauer, B.; Miller, D. S.; Schaffrik, M.; Fankhanel, M.;Spruss, T.; Bernhardt, G.; Graeff, C.; Farber, L.; Gschaidmeier, H.;Buschauer, A.; Fricker, G., Transport of paclitaxel (Taxol) acrossthe blood-brain barrier in vitro and in vivo. J. Clin. Invest., 2002,110 (9), 1309-1318. (Pubitemid 35285757)
17. Friedenberg, W. R.; Rue, M.; Blood, E. A.; Dalton, W. S.; Shustik,C.; Larson, R. A.; Sonneveld, P.; Greipp, P. R., Phase III study ofPSC-833 (Valspodar) in combination with vincristine, doxorubicin,and dexamethasone (Valspodar/VAD) versus VAD alone inpatients with recurring or refractory multiple myeloma (E1A95) -A Trial of the Eastern Cooperative Oncology Group. Cancer, 2006,106 (4), 830-838. (Pubitemid 43238450)
18. Hyafil, F.; Vergely, C.; Duvignaud, P.; Grandperret, T., In-Vitroand in-Vivo Reversal of Multidrug-Resistance by Gf120918, anAcridonecarboxamide Derivative. Cancer Res., 1993, 53 (19),4595-4602. (Pubitemid 23304385)
19. Roe, M.; Folkes, A.; Ashworth, P.; Brumwell, J.; Chima, L.;Hunjan, S.; Pretswell, I.; Dangerfield, W.; Ryder, H.; Charlton, P.,Reversal of P-glycoprotein mediated multidrug resistance by novelanthranilamide derivatives. Bioorg. Med. Chem. Lett., 1999, 9 (4),595-600. (Pubitemid 29090660)
20. Shepard, R. L.; Cao, J.; Starling, J. J.; Dantzig, A. H., Modulationof P-glycoprotein but not MRP1- or BCRP-mediated drugresistance by LY335979. International Journal of Cancer, 2003,103 (1), 121-125. (Pubitemid 35424215)
21. Dantzig, A. H.; Shepard, R. L.; Cao, J.; Law, K. L.; Ehlhardt, W.J.; Baughman, T. M.; Bumol, T. F.; Starling, J. J., Reversal of Pglycoprotein- mediated multidrug resistance by a potentcyclopropyldibenzosuberane modulator, LY335979. Cancer Res.,1996, 56 (18), 4171-4179. (Pubitemid 26305012)
22. Planting, A. S. T.; Sonneveld, P.; van der Gaast, A.; Sparreboom,A.; van der Burg, M. E. L.; Luyten, G. P. M.; de Leeuw, K.; deBoer-Dennert, M.; Wissel, P. S.; Jewell, R. C.; Paul, E. M.; Purvis,N. B.; Verweij, J., A phase I and pharmacologic study of the MDRconverter GF120918 in combination with doxorubicin in patientswith advanced solid tumors. Cancer Chemotherapy andPharmacology, 2005, 55 (1), 91-99. (Pubitemid 40064500)
23. Hubensack, M.; Mü ller, C.; Höcherl, P.; Fellner, S.; Spruss, T.;Bernhardt, G.; Buschauer, A., Effect of the ABCB1 modulatorselacridar and tariquidar on the distribution of paclitaxel in nudemice. Journal of Cancer Research and Clinical Oncology, 2008,134 (5), 597-607. (Pubitemid 351422612)
24. Kemper, E. M.; Verheij, M.; Boogerd, W.; Beijnen, J. H.; vanTellingen, O., Improved penetration of docetaxel into the brain byco-administration of inhibitors of P-glycoprotein. Eur. J. Cancer,2004, 40 (8), 1269-1274. (Pubitemid 38526348)
25. Sparreboom, A.; Planting, A. S. T.; Jewell, R. C.; van der Burg, M.E. L.; van der Gaast, A.; de Bruijn, P.; Loos, W. J.; Nooter, K.;Chandler, L. H.; Paul, E. M.; Wissel, P. S.; Verweij, J., Clinicalpharmacokinetics of doxorubicin in combination with GF120918, apotent inhibitor of MDR1 P-glycoprotein. Anti-Cancer Drug, 1999,10 (8), 719-728. (Pubitemid 30015673)
26. de Bruin, M.; Miyake, K.; Litman, T.; Robey, R.; Bates, S. E.,Reversal of resistance by GF120918 in cell lines expressing theABC half-transporter, MXR. Cancer Letters, 1999, 146 (2), 117-126. (Pubitemid 29492880)
27. Allen, J. D.; Brinkhuis, R. F.; Wijnholds, J.; Schinkel, A. H., TheMouse Bcrp1/Mxr/Abcp Gene. Cancer Res. 1999, 59 (17), 4237-4241.
28. Maliepaard, M.; van Gastelen, M. A.; Tohgo, A.; Hausheer, F. H.;van Waardenburg, R.; de Jong, L. A.; Pluim, D.; Beijnen, J. H.;Schellens, J. H. M., Circumvention of breast cancer resistanceprotein (BCRP)-mediated resistance to camptothecins in vitro usingnon-substrate drugs or the BCRP inhibitor GF120918. ClinicalCancer Research, 2001, 7 (4), 935-941. (Pubitemid 32708732)
29. Martin, C.; Berridge, G.; Mistry, P.; Higgins, C.; Charlton, P.;Callaghan, R., The molecular interaction of the high affinityreversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol.1999, 128 (2), 403-411. (Pubitemid 29458600)
30. Mistry, P.; Stewart, A. J.; Dangerfield, W.; Okiji, S.; Liddle, C.;Bootle, D.; Plumb, J. A.; Templeton, D.; Charlton, P., In vitro andin vivo reversal of P-glycoprotein-mediated multidrug resistance bya novel potent modulator, XR9576. Cancer Res., 2001, 61 (2), 749-758. (Pubitemid 32128642)
31. Stewart, A.; Steiner, J.; Mellows, G.; Laguda, B.; Norris, D.;Bevan, P., Phase I trial of XR9576 in healthy volunteersdemonstrates modulation of P-glycoprotein in CD56(+)lymphocytes after oral and intravenous administration. ClinicalCancer Research., 2000, 6 (11), 4186-4191.
32. Abraham, J.; Edgerly, M.; Wilson, R.; Medina, W.; Hermonstine,L.; Rutt, A.; Bakke, S.; Robey, R.; Grem, J.; Bates, S.; Fojo, T.;Chen, C.; Dwyer, A.; Goldspiel, B.; Van Tellingen, O.; Norris, D.;Steiner, J.; Waterfall, J., A study of the novel P-glycoprotein (P-gp)antagonist, XR9576 in combination with vinorelbine. ClinicalCancer Research., 2001, 7 (11), 3739s-3740s.
33. Pusztai, L.; Wagner, P.; Ibrahim, N.; Rivera, E.; Theriault, R.;Booser, D.; Symmans, F. W.; Wong, F.; Blumenschein, G.;Fleming, D. R.; Rouzier, R.; Boniface, G.; Hortobagyi, G. N.,Phase II study of tariquidar, a selective P-glycoprotein inhibitor, inpatients with chemotherapy-resistant, advanced breast carcinoma.Cancer, 2005, 104 (4), 682-691. (Pubitemid 41114904)
34. QLT Inc Press Releases 2003.http://www.qltinc.com/newsCenter/2003.htm.
35. Dantzig, A. H.; Shepard, R. L.; Law, K. L.; Tabas, L.; Pratt, S.;Gillespie, J. S.; Binkley, S. N.; Kuhfeld, M. T.; Starling, J. J.;Wrighton, S. A., Selectivity of the Multidrug ResistanceModulator, LY335979, for P-Glycoprotein and Effect onCytochrome P-450 Activities. Journal of Pharmacology andExperimental Therapeutics, 1999, 290 (2), 854-862. (Pubitemid 29344586)
36. Tang, R.; Faussat, A.; Perrot, J.; Marjanovic, Z.; Cohen, S.;Storme, T., Zosuquidar restores drug sensitivity in P-glycoproteinexpressing acute myeloid leukemia (AML). BMC Cancer,2008, 8.
37. Rubin, E. H.; de Alwis, D. P.; Pouliquen, I.; Green, L.; Marder, P.;Lin, Y.; Musanti, R.; Grospe, S. L.; Smith, S. L.; Toppmeyer, D.L.; Much, J.; Kane, M.; Chaudhary, A.; Jordan, C.; Burgess, M.;Slapak, C. A., A Phase I Trial of a Potent P-Glycoprotein Inhibitor,Zosuquidar.3HCl Trihydrochloride (LY335979), AdministeredOrally in Combination with Doxorubicin in Patients with AdvancedMalignancies. Clinical Cancer Research, 2002, 8 (12), 3710-3717. (Pubitemid 35424760)
38. Sandler, A.; Gordon, M.; de Alwis, D. P.; Pouliquen, I.; Green, L.;Marder, P.; Chaudhary, A.; Fife, K.; Battiato, L.; Sweeney, C.;Jordan, C.; Burgess, M.; Slapak, C. A., A Phase I Trial of a PotentP-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride(LY335979), Administered Intravenously in Combination withDoxorubicin in Patients with Advanced Malignancy. ClinicalCancer Research, 2004, 10 (10), 3265-3272. (Pubitemid 38685430)
39. Morschhauser, F.; Zinzani, P. L.; Burgess, M.; Sloots, L.; Bouafia,F.; Dumontet, C., Phase I/II trial of a P-glycoprotein inhibitor,Zosuquidar. 3HCl trihydrochloride ( LY335979), given orally incombination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk. Lymphoma, 2007, 48 (4), 708-715. (Pubitemid 46605542)
40. Lê, L. H.; Moore, M. J.; Siu, L. L.; Oza, A. M.; MacLean, M.;Fisher, B.; Chaudhary, A.; Alwis, D. P. d.; Slapak, C.; Seymour, L.,Phase I study of the multidrug resistance inhibitor zosuquidaradministered in combination with vinorelbine in patients withadvanced solid tumours. Cancer Chemotherapy andPharmacology, 2005, 56 (2), 154-160. (Pubitemid 40884270)
41. Ross, D. D.; Wooten, P. J.; Tong, Y.; Cornblatt, B.; Levy, C.;Sridhara, R.; Lee, E. J.; Schiffer, C. A., Synergistic Reversal ofMultidrug-Resistance Phenotype in Acute Myeloid-Leukemia Cellsby Cyclosporine-a and Cremophor El. Blood, 1994, 83 (5), 1337-1347. (Pubitemid 24062857)
42. Hwang, M.; Ahn, C. H.; Pine, P. S.; Yin, J. J.; Hrycyna, C. A.;Licht, T.; Aszalos, A., Effect of combination of suboptimal,concentrations of p-glycoprotein blockers on the proliferation ofMDR1 gene expressing cells. International Journal of Cancer,1996, 65 (3), 389-397. (Pubitemid 26059991)
43. Ji, B. S.; Li, M.; He, L., Effect of CJX2, an Amlodipine Derivative,Combined With Verapamil on P-Glycoprotein Efflux Function InVitro. Drug Develop Res 2009, 70 (6), 445-449.
44. Choi, J. S.; Han, H. K., Enhanced oral exposure of diltiazem by theconcomitant use of naringin in rats. Int. J. Pharm., 2005, 305 (1-2),122-128.
45. Li, X. G.; Choi, J. S., Effect of genistein on the pharmacokineticsof paclitaxel administered orally or intravenously in rats. Int. J.Pharm., 2007, 337 (1-2), 188-193.
46. Jin, J.; Bi, H.; Hu, J.; Zhong, G.; Zhao, L.; Huang, Z.; Huang, M.,Enhancement of oral bioavailability of paclitaxel after oraladministration of Schisandrol B in rats. Biopharmaceutics & DrugDisposition, 2010, 31 (4), 264-268.
47. Molnar, J.; Engi, H.; Hohmann, J.; Molnar, P.; Deli, J.;Wesolowska, O.; Michalak, K.; Wang, Q., Reversal of MultidrugResistance by Natural Substances from Plants. Curr. Top. Med.Chem., 2010, 10 (17), 1757-1768.
48. Huang, M.; Jin, J.; Sun, H.; Liu, G. T., Reversal of P- glycoproteinmediatedmultidrug resistance of cancer cells by five schizandrinsisolated from the Chinese herb Fructus Schizandrae. CancerChemotherapy and Pharmacology, 2008, 62 (6), 1015-1026.
49. Kosina, P.; Maurel, P.; Ulrichova, J.; Dvorak, Z., Effect of silybinand its glycosides on the expression of cytochromes p450 1A2 and3A4 in primary cultures of human hepatocytes. J. Biochem. Mol.Toxic, 2005, 19 (3), 149-153. (Pubitemid 40967281)
50. Zuber, R.; Modriansky, M.; Dvorak, Z.; Rohovsky, P.; Ulrichova,J.; Simanek, V.; Anzenbacher, P., Effect of silybin and itscongeners on human liver microsomal cytochrome P450 activities.Phytother. Res., 2002, 16 (7), 632-638. (Pubitemid 35334183)
51. Giacomelli, S.; Gallo, D.; Apollonio, P.; Ferlini, C.; Distefano, M.;Morazzoni, P.; Riva, A.; Bombardelli, E.; Mancuso, S.; Scambia,G., Silybin and its bioavailable phospholipid complex (IdB 1016)potentiate in vitro and in vivo the activity of cisplatin. Life Sci2002, 70 (12), 1447-1459. (Pubitemid 34159100)
52. Zhang, S. H.; Morris, M. E., Effects of the flavonoids biochanin A,morin, phloretin, and silymarin on P-glycoprotein-mediatedtransport. Journal of Pharmacology and ExperimentalTherapeutics 2003, 304 (3), 1258-1267. (Pubitemid 36254439)
53. Zhang, S. Z.; Morris, M. E., Effect of the flavonoids biochanin Aand silymarin on the P-glycoprotein-mediated transport of digoxinand vinblastine in human intestinal Caco-2 cells. Pharm. Res.,2003, 20 (8), 1184-1191. (Pubitemid 36951843)
54. Lee, C. K.; Choi, J. S., Effects of Silibinin, Inhibitor of CYP3A4and P-Glycoprotein in vitro, on the Pharmacokinetics of Paclitaxelafter Oral and Intravenous Administration in Rats. Pharmacology,2010, 85 (6), 350-356.
55. Dzubak, P.; Hajduch, M.; Gazak, R.; Svobodova, A.; Psotova, J.;Walterova, D.; Sedmera, P.; Kren, V., New derivatives of silybinand 2,3-dehydrosilybin and their cytotoxic and P-glycoproteinmodulatory activity. Bioorgan. Med. Chem., 2006, 14 (11), 3793-3810.
56. Duarte, N.; Jardanhazy, A.; Molnar, J.; Hilgeroth, A.; Ferreira, M.J. U., Synergistic interaction between p-glycoprotein modulatorsand epirubicine on resistant cancer cells. Bioorgan. Med. Chem.,2008, 16 (20), 9323-9330.
57. Jung, H.; Chung, S.; Nam, J. W.; Chae, S.; Lee, Y. J.; Seo, E. K.;Lee, H., Inhibition of P-Glycoprotein-Induced MultidrugResistance by a Clerodane-Type Diterpenoid from Sindorasumatrana. Chem. Biodivers., 2010, 7 (8), 2095-2101.
58. Yu, T.; Li, J.; Sun, H., Syl611, a novel semisynthetic taxanederivative, reverses multidrug resistance by p-glycoproteininhibition and facilitating inward transmembrane action. CancerChemotherapy and Pharmacology, 2010, 66 (5), 999-1003.
59. Xi, G.-m.; Sun, B.; Jiang, H.-H.; Kong, F.; Yuan, H.-q.; Lou, H.-x.,Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCRcells to chemotherapeutic agents by retarding P-gp activity. Bioorg.Med. Chem., 2010, 18 (18), 6725-33.
60. Kim, S. W.; Kwon, H.; Chi, D. W.; Shim, J. H.; Park, J. D.; Lee, Y.H.; Pyo, S.; Rhee, D. K., Reversal of P-glycoprotein-mediatedmultidrug resistance by ginsenoside Rg(3). Biochem. Pharmacol.,2003, 65 (1), 75-82. (Pubitemid 35447841)
61. Yoshida, N.; Koizumi, M.; Adachi, I.; Kawakami, J., Inhibition ofP-glycoprotein-mediated transport by terpenoids contained inherbal medicines and natural products. Food Chem. Toxicol., 2006,44 (12), 2033-2039. (Pubitemid 44537561)
62. Jain, S.; Abraham, I.; Carvalho, P.; Kuang, Y. H.; Shaala, L. A.;Youssef, D. T. A.; Avery, M. A.; Chen, Z. S.; El Sayed, K. A.,Sipholane Triterpenoids: Chemistry, Reversal of ABCB1/PGlycoprotein-Mediated Multidrug Resistance, and Pharmacophore Modeling. J. Nat. Prod., 2009, 72 (7), 1291-1298.
63. Qiang, F.; Lee, B. J.; Ha, I.; Kang, K. W.; Woo, E. R.; Han, H. K.,Effect of maceligan on the systemic exposure of paclitaxel: In vitroand in vivo evaluation. Eur. J. Pharm. Sci., 2010, 41 (2), 226-231.
64. Molnar, J.; Gyemant, N.; Tanaka, M.; Mucsi, I.; Ugocsai, K.;Hohmann, J.; Ferreira, M. J. U.; Molnar, P.; Didiziapetris, R.,Reversal of Multidrug Resistance: Modification of RhodamineAccumulation by Selected Flavonoids and Carotenoids and RelatedCompounds. Anticancer Res, 2004, 24 (5D), 3568-3568.
65. Molnar, J.; Gyemant, N.; Mucsi, I.; Molnar, A.; Szabo, M.;Kortvelyesi, T.; Varga, A.; Molnar, P.; Toth, G., Modulation ofmultidrug resistance and apoptosis of cancer cells by selectedcarotenoids. In Vivo., 2004, 18 (2), 237-244. (Pubitemid 38489008)
66. Molnár, P.; Kawase, M.; Satoh, K.; Sohara, Y.; Tanaka, T.; Tani,S.; Sakagami, H.; Nakashima, H.; Motohashi, N.; Gyémánt, N.;Molnár, J., Biological activity of carotenoids in red paprika,Valencia orange and Golden delicious apple. Phytother. Res., 2005,19 (8), 700-707. (Pubitemid 41433635)
67. Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; MatakVinković , D.; Jhoti, H., Crystal structure of human cytochromeP450 2C9 with bound warfarin. Nature, 2003, 424 (6947), 464-8. (Pubitemid 36917499)
68. Yano, J. K.; Denton, T. T.; Cerny, M. A.; Zhang, X. D.; Johnson,E. F.; Cashman, J. R., Synthetic inhibitors of cytochrome P-4502A6: Inhibitory activity, difference spectra, mechanism ofinhibition, and protein cocrystallization. J. Med. Chem., 2006, 49(24), 6987-7001. (Pubitemid 44885987)
69. Ekroos, M.; Sjogren, T., Structural basis for ligand promiscuity incytochrome P450 3A4. P Natl Acad Sci USA 2006, 103 (37),13682-13687. (Pubitemid 44413967)
70. Ahlström, M. M.; Ridderström, M.; Zamora, I., CYP2C9 structuremetabolismrelationships: substrates, inhibitors, and metabolites. J.Med. Chem., 2007, 50 (22), 5382-91. (Pubitemid 350064000)
71. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.P.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q. H.; Urbatsch, I. L.;Chang, G., Structure of P-Glycoprotein Reveals a Molecular Basisfor Poly-Specific Drug Binding. Science, 2009, 323 (5922), 1718-1722.
72. O'Mara, M. L.; Tieleman, D. P., P-glycoprotein models of the apoand ATP-bound states based on homology with Sav1866 andMalK. FEBS Lett., 2007, 581 (22), 4217-22. (Pubitemid 47301854)
73. Stockner, T.; de Vries, S. J.; Bonvin, A. M. J. J.; Ecker, G. F.;Chiba, P., Data-driven homology modelling of P-glycoprotein inthe ATP-bound state indicates flexibility of the transmembranedomains. FEBS J., 2009, 276 (4), 964-72.
74. Fischer, G.; Kosinska-Eriksson, U.; Aponte-Santamaría, C.;Palmgren, M.; Geijer, C.; Hedfalk, K.; Hohmann, S.; de Groot, B.L.; Neutze, R.; Lindkvist-Petersson, K., Crystal Structure of aYeast Aquaporin at 1.15 Å Reveals a Novel Gating Mechanism.PLoS Biol., 2009, 7 (6), e1000130.
75. Horsefield, R.; Nordén, K.; Fellert, M.; Backmark, A.; Törnroth-Horsefield, S.; Terwisscha van Scheltinga, A. C.; Kvassman, J.;Kjellbom, P.; Johanson, U.; Neutze, R., High-resolution x-raystructure of human aquaporin 5. Proceedings of the NationalAcademy of Sciences 2008, 105 (36), 13327-13332.
76. Tornroth-Horsefield, S.; Wang, Y.; Hedfalk, K.; Johanson, U.;Karlsson, M.; Tajkhorshid, E.; Neutze, R.; Kjellbom, P., Structuralmechanism of plant aquaporin gating. Nature, 2006, 439 (7077),688-694.
77. Molina, D. M.; Wetterholm, A.; Kohl, A.; McCarthy, A. A.;Niegowski, D.; Ohlson, E.; Hammarberg, T.; Eshaghi, S.;Haeggstrom, J. Z.; Nordlund, P., Structural basis for synthesis ofinflammatory mediators by human leukotriene C4 synthase.Nature, 2007, 448 (7153), 613-616. (Pubitemid 47208483)
78. Jaakola, V.-P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.;Chien, E. Y. T.; Lane, J. R.; Ijzerman, A. P.; Stevens, R. C., The2.6 angstrom crystal structure of a human A2A adenosine receptorbound to an antagonist. Science, 2008, 322 (5905), 1211-7.
79. Kolb, P.; Rosenbaum, D. M.; Irwin, J. J.; Fung, J. J.; Kobilka, B.K.; Shoichet, B. K., Structure-based discovery of beta2-adrenergicreceptor ligands. Proc. Natl,. Acad. Sci. USA ,2009, 106 (16),6843-8.
80. Crowley, E.; McDevitt, C. A.; Callaghan, R., Generating Inhibitorsof P-Glycoprotein: Where to, Now? 2009; Vol. 596, pp 405-432.
81. Wang, R. B.; Kuo, C. L.; Lien, L. L.; Lien, E. J., Structure- activityrelationship: analyses of p-glycoprotein substrates and inhibitors. J.Clin. Pharm. Ther., 2003, 28 (3), 203-228. (Pubitemid 36783098)
82. Pajeva, I. K.; Wiese, M., Pharmacophore model of drugs involvedin P-glycoprotein multidrug resistance: Explanation of structuralvariety (Hypothesis). J. Med. Chem., 2002, 45 (26), 5671-5686. (Pubitemid 35453760)
83. Pajeva, I. K.; Globisch, C.; Wiese, M., Combined PharmacophoreModeling, Docking, and 3D QSAR Studies of ABCB1 and ABCC1Transporter Inhibitors. ChemMedChem, 2009, 4 (11), 1883-1896.
84. Hajduk, P. J.; Greer, J., A decade of fragment-based drug design:strategic advances and lessons learned. Nat. Rev. Drug Discov.,2007, 6 (3), 211-9. (Pubitemid 46344625)
85. Wyatt, P. G.; Woodhead, A. J.; Berdini, V.; Boulstridge, J. A.;Carr, M. G.; Cross, D. M.; Davis, D. J.; Devine, L. A.; Early, T. R.;Feltell, R. E.; Lewis, E. J.; McMenamin, R. L.; Navarro, E. F.;O'Brien, M. A.; O'Reilly, M.; Reule, M.; Saxty, G.; Seavers, L. C.A.; Smith, D.-M.; Squires, M. S.; Trewartha, G.; Walker, M. T.;Woolford, A. J.-A., Identification of N-(4-piperidinyl)-4-(2, 6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), anovel cyclin dependent kinase inhibitor using fragment-based Xraycrystallography and structure based drug design. J. Med.Chem., 2008, 51 (16), 4986-99.
86. Poirier, J.; Delisle, M. C.; Quirion, R.; Aubert, I.; Farlow, M.;Lahiri, D.; Hui, S.; Bertrand, P.; Nalbantoglu, J.; Gilfix, B. M.;Gauthier, S., Apolipoprotein E4 allele as a predictor of cholinergicdeficits and treatment outcome in Alzheimer disease. Proc. Natl.Acad. Sci. USA., 1995, 92 (26), 12260-4. (Pubitemid 26014050)
87. Fung, K. L.; Gottesman, M. M., A synonymous polymorphism in acommon MDR1 (ABCB1) haplotype shapes protein function.Biochim. Biophys. Acta, 2009, 1794 (5), 860-71.
88. Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H. P.;Brockmöller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.;Eichelbaum, M.; Brinkmann, U., Functional polymorphisms of thehuman multidrug-resistance gene: multiple sequence variations andcorrelation of one allele with P-glycoprotein expression andactivity in vivo. Proc. Natl. Acad. Sci. USA., 2000, 97 (7), 3473-8. (Pubitemid 30183327)
89. Kimchi-Sarfaty, C.; Oh, J. M.; Kim, I.-W.; Sauna, Z. E.; Calcagno,A. M.; Ambudkar, S. V.; Gottesman, M., A "silent" polymorphismin the MDR1 gene changes substrate specificity. Science, 2007, 315(5811), 525-8.
90. Owen, A.; Goldring, C.; Morgan, P.; Chadwick, D.; Park, B. K.;Pirmohamed, M., Relationship between the C3435T andG2677T(A) polymorphisms in the ABCB1 gene and Pglycoproteinexpression in human liver. Br. J. Clin. Pharmacol.,2005, 59 (3), 365-70. (Pubitemid 40388091)
91. Hitzl, M.; Schaeffeler, E.; Hocher, B.; Slowinski, T.; Halle, H.;Eichelbaum, M.; Kaufmann, P.; Fritz, P.; Fromm, M. F.; Schwab,M., Variable expression of P-glycoprotein in the human placentaand its association with mutations of the multidrug resistance 1gene (MDR1, ABCB1). Pharmacogenetics, 2004, 14 (5), 309-18. (Pubitemid 38638918)
92. Patil, Y. B.; Swaminathan, S. K.; Sadhukha, T.; Ma, L.; Panyam, J.,The use of nanoparticle-mediated targeted gene silencing and drugdelivery to overcome tumor drug resistance. Biomaterials, 2010, 31(2), 358-365.
93. Karagiannis, E. D.; Anderson, D. G., Minicells overcome tumordrug-resistance. Nat. Biotech., 2009, 27 (7), 620-621.
94. MacDiarmid, J. A.; Mugridge, N. B.; Weiss, J. C.; Phillips, L.;Burn, A. L.; Paulin, Richard P.; Haasdyk, J. E.; Dickson, K.-A.;Brahmbhatt, V. N.; Pattison, S. T.; James, A. C.; Al Bakri, G.;Straw, R. C.; Stillman, B.; Graham, R. M.; Brahmbhatt, H.,Bacterially Derived 400 nm Particles for Encapsulation and CancerCell Targeting of Chemotherapeutics. Cancer cell, 2007, 11 (5),431-445. (Pubitemid 46670079)
95. MacDiarmid, J. A.; Amaro-Mugridge, N. B.; Madrid-Weiss, J.;Sedliarou, I.; Wetzel, S.; Kochar, K.; Brahmbhatt, V. N.; Phillips,L.; Pattison, S. T.; Petti, C.; Stillman, B.; Graham, R. M.;Brahmbhatt, H., Sequential treatment of drug-resistant tumors withtargeted minicells containing siRNA or a cytotoxic drug. Nat.Biotech., 2009, 27 (7), 643-651.
96. WHO Drug Information [Online], 2002.http://apps.who.int/medicinedocs/en/ d/Js4952e/4.1.html.
97. Fox, J., Gene therapy safety issues come to fore. Nat Biotech 1999,17 (12), 1153.
98. Loo, L.; Guenther, R. H.; Lommel, S. A.; Franzen, S., Infusion ofdye molecules into Red clover necrotic mosaic virus. Chem.Commun., 2008, (1), 88-90. (Pubitemid 350264890)
99. Sarkar, D.; Lebedeva, I. V.; Su, Z.-z.; Park, E.-S.; Chatman, L.;Vozhilla, N.; Dent, P.; Curiel, D. T.; Fisher, P. B., Eradication ofTherapy-Resistant Human Prostate Tumors Using a CancerTerminator Virus. Cancer Res., 2007, 67 (11), 5434-5442. (Pubitemid 46997284)
100. Sarkar, D.; Su, Z. Z.; Park, E. S.; Vozhilla, N.; Dent, P.; Curiel, D.T.; Fisher, P. B., A cancer terminator virus eradicates both primaryand distant human melanomas. Cancer Gene Ther., 2008, 15 (5),293-302. (Pubitemid 351508135)
101. Hwang, S.-K.; Lim, H.-T.; Minai-Tehrani, A.; Lee, E.-S.; Park, J.;Park, S. B.; Beck, G. R., Jr.; Cho, M.-H., Repeated AerosolDelivery of Carboxyl-terminal Modulator Protein SuppressesTumor in the Lungs of K-rasLA1 Mice. Am. J. Respir. Crit. CareMed., 2009, 179 (12), 1131-1140.
102. Kolitz, J. E.; George, S. L.; Marcucci, G.; Vij, R.; Powell, B. L.;Allen, S. L.; DeAngelo, D. J.; Shea, T. C.; Stock, W.; Baer, M. R.;Hars, V.; Maharry, K.; Hoke, E.; Vardiman, J. W.; Bloomfield, C.D.; Larson, R. A.; Cancer; Leukemia Group, B., P-glycoproteininhibition using valspodar (PSC-833) does not improve outcomesfor patients younger than age 60 years with newly diagnosed acutemyeloid leukemia: Cancer and Leukemia Group B study 19808.Blood, 2010, 116 (9), 1413-21.
103. Smith, B. L.; Chin, D.; Maltzman, W.; Crosby, K.; Hortobagyi, G.N.; Bacus, S. S., The efficacy of Herceptin therapies is influencedby the expression of other erbB receptors, their ligands and theactivation of downstream signalling proteins. Br. J. Cancer, 2004,91 (6), 1190-1194. (Pubitemid 39336261)
104. Mathieu, Paraxel's Bio/Pharmaceutical R&D Stastical Sourcebook2008/2009. 2009.
105. Fruttero, R.; Crosetti, M.; Chegaev, K.; Guglielmo, S.; Gasco, A.;Berardi, F.; Niso, M.; Perrone, R.; Panaro, M. A.; Colabufo, N. A.,Phenylsulfonylfuroxans as Modulators of Multidrug-Resistance-Associated Protein-1 and P-Glycoprotein. J. Med. Chem., 2010, 53(15), 5467-5475.
106. Riganti, C.; Miraglia, E.; Viarisio, D.; Costamagna, C.;Pescarmona, G.; Ghigo, D.; Bosia, A., Nitric oxide reverts theresistance to doxorubicin in human colon cancer cells by inhibitingthe drug efflux. Cancer Res., 2005, 65 (2), 516-525.